Zobrazeno 1 - 10
of 11 493
pro vyhledávání: '"Proteasome inhibitor"'
Autor:
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z. Parris
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-20 (2024)
Abstract Repurposing of FDA-approved drugs is a quick and cost-effective alternative to de novo drug development. Here, we identify genes involved in bortezomib sensitivity, predict cancer types that may benefit from treatment with bortezomib, and ev
Externí odkaz:
https://doaj.org/article/cb8556dc4f164843a07201a962a40d0f
Autor:
Deng Yao, Li Yujie, Yang Mingyue, Gao Yang, Luo Xuling, Chen Hanbin, Guo Meng, Yang Xuefeng, Liu Yongzhang, He Jun, Lu Bin, Liu Naxin
Publikováno v:
Acta Biochimica et Biophysica Sinica, Vol 56, Pp 697-708 (2024)
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly cancers in the world, which is frequently diagnosed at a late stage. HCC patients have a poor prognosis due to the lack of an efficacious therapeutic strategy. Approved drug repur
Externí odkaz:
https://doaj.org/article/20fd18914ec644fbaf8cd1a1c55e5964
Autor:
Xiaobin Wang, Yingqing Shi, Hua Shi, Xiaoyu Liu, Aijun Liao, Zhuogang Liu, Robert Z. Orlowski, Rui Zhang, Huihan Wang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-21 (2024)
Abstract Background Proteasome inhibitors (PIs) are one of the most important classes of drugs for the treatment of multiple myeloma (MM). However, almost all patients with MM develop PI resistance, resulting in therapeutic failure. Therefore, the me
Externí odkaz:
https://doaj.org/article/3a20e089963e4841a3ed354fd16b61a4
Autor:
Wei Huang, Xia Yuan, Ting Sun, Shujie Fan, Jun Wang, Quan Zhou, Wei Guo, Fuxiang Ran, Zemei Ge, Huayu Yang, Runtao Li, Jingrong Cui
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/5c78fa88e4e04a34965e99e1cdd70df2
Autor:
Tran Tran Thi Van, Hsun-Shuo Chang, Ho-Cheng Wu, Chung-Kuang Lu, Hui-Chi Huang, Michal Korinek, Hui-Hua Hsiao, Chia-Hung Yen
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Bortezomib (BTZ), a primary treatment for MM, but its effectiveness can be reduced by interactions with vicinal diol moieties (VDMs) in polyphenols. Despite this, it’s debated whether BTZ therapy necessitates avoiding polyphenol-rich pr
Externí odkaz:
https://doaj.org/article/9fb452b1035d4f45b211c79b9d20ab50
Publikováno v:
Genes and Diseases, Vol 11, Iss 4, Pp 101070- (2024)
Protein homeostasis is the basis of normal life activities, and the proteasome family plays an extremely important function in this process. The proteasome 20S is a concentric circle structure with two α rings and two β rings overlapped. The protea
Externí odkaz:
https://doaj.org/article/2ed222aca2884ec1bad619ea4714c70c
Publikováno v:
Shipin Kexue, Vol 44, Iss 24, Pp 112-117 (2023)
In this study, the Longissimus dorsi muscle of Qinchuan cattle was injected with the proteasome inhibitor MG-132 immediately postmortem and then stored at 4 ℃. The effect of the ubiquitin-proteasome pathway (UPP) on protein degradation as well as c
Externí odkaz:
https://doaj.org/article/8e284ff1b5d24d9b8bd38b02ece8f43f
Autor:
Hae Chan Park, Hyojin Kim, Ji-Yeong Kim, Hye-Yeon Lee, Jinyi Lee, WonJae Cha, Soon-Hyun Ahn, Woo-Jin Jeong
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Despite the diverse genetic mutations in head and neck cancer, the chemotherapy outcome for this cancer has not improved for decades. It is urgent to select prognostic factors and therapeutic targets for oropharyngeal cancer to es
Externí odkaz:
https://doaj.org/article/ba20304a071844b2ae870c53b393aecf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Aijun Liu, Hong Yu, Rui Hou, Zunmin Zhu, Jun‐ling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, Arong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Rong Fu, Deqiang Zheng, Wenming Chen
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Objective To evaluate the effectiveness, safety, and convenience of in‐class transition (iCT) from intravenous bortezomib‐based induction to ixazomib‐based oral regimens. Methods This retrospective real‐world study was conducted in 1
Externí odkaz:
https://doaj.org/article/baaecafcf2aa4b06bececf87315f3141